 |
FDA Tequin
| Date: | Monday February 6, 2006 |
| Type: | Task
(Public)
|
Tequin (gatifloxacin)
Audience: Healthcare professionals and patients
[Posted 02/16/2006] BMS notified FDA and healthcare professionals about proposed changes to the prescribing information for Tequin, including an updating of the existing WARNING on hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar), and a CONTRAINDICATION for use in diabetic patients. The changes also include information identifying other risk factors for developing low blood sugar and high blood sugar, including advanced age, renal insufficiency, and concomitant glucose-altering medications while takin |
|
